SHANGHAI, Nov 28 (Reuters) - AstraZeneca's AZN.L blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an update from the National Healthcare Security Administration.
The antibody-drug conjugate, commonly known as Enhertu, is among the drugs that will be added to China's state-run medical insurance from Jan. 1, the list showed.
Enhertu, co-developed with Japan's Daiichi Sankyo 4568.T partly for breast cancer patients with HER-2 positive disease, is designed to deliver toxic chemotherapy directly to tumors.
The HER2 protein contributes to the growth and spread of breast cancer. About one in five patients with breast cancer are considered HER2-positive, according to AstraZeneca.
For females in China, breast cancer is the second most frequent cancer after lung cancer, according to 2022 estimates from the International Agency for Research on Cancer.
A spokesperson for Astra Zeneca referred Reuters to a National Healthcare Security Administration government announcement. Daiichi Sankyo did not immediately respond to requests for comment.
(Reporting by Andrew Silver; Editing by Kirsten Donovan)
((andrew.silver@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。